help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
First Published Online July 16, 2009
The Oncologist, Vol. 14, No. 7, 683-694, July 2009; doi:10.1634/theoncologist.2008-0275
© 2009 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2008-0275v1
14/7/683    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Google Scholar
Right arrow Articles by Helm, C. W.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Helm, C. W.

Gynecologic Oncology

The Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer

C. William Helm

James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA

Key Words. Hyperthermic intraperitoneal chemotherapy (HIPEC) • Ovarian neoplasms • Intraperitoneal chemotherapy • Hyperthermia • Cytoreductive surgery

Correspondence: C. William Helm, M.B.B.Chir., F.R.C.S., F.A.C.O.G., Division of Gynecologic Oncology, Third Floor, James Graham Brown Cancer Center, 529 South Jackson Street, Louisville, Kentucky 40202, USA. Telephone: 502-561-7254; Fax: 502-561-7205; e mail: cwhelm{at}uoflobgyn.com

Received December 10, 2008; accepted for publication May 6, 2009; first published online in THE ONCOLOGIST Express on July 16, 2009.

Disclosures: C. William Helm: Honoraria: ThermaSolutions, Inc; Research funding/contracted research: ThermaSolutions, Inc, Sanofi-Aventis.

The devices discussed in this article are, to the author's knowledge, not FDA-approved for intraperitoneal delivery.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.

Overall outcomes for women with epithelial ovarian cancer (EOC) remain relatively poor, and superior methods of treatment are needed. EOC is a peritoneal surface malignancy that is relatively sensitive to chemotherapy agents, making it a good target for i.p. chemotherapy. Because there is strong laboratory data demonstrating the ability of hyperthermia to increase the efficacy of chemotherapeutic agents, the addition of hyperthermia to i.p. chemotherapy, hyperthermic intraperitoneal chemotherapy (HIPEC), makes theoretical sense. This article reviews the current literature and discusses the possible role for HIPEC in EOC at significant natural history time points: front line, at the time of interval debulking, in consolidation, and for recurrent disease. The conclusion is that much further research is needed but that HIPEC could sensibly be researched at all the natural history time points in EOC.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2009 by AlphaMed Press.